

## **Clinical Policy: Clobazam (Onfi)**

Reference Number: CP.PMN.54

Effective Date: 11.01.12

Last Review Date: 11.18

Line of Business: HIM, Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

### **Description**

Clobazam (Onfi<sup>®</sup>) is a benzodiazepine.

### **FDA Approved Indication(s)**

Onfi is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.

### **Policy/Criteria**

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that Onfi is **medically necessary** when the following criteria are met:

#### **I. Initial Approval Criteria**

##### **A. Lennox-Gastaut Syndrome (must meet all):**

1. Diagnosis of LGS;
2. Prescribed by or in consultation with a neurologist;
3. Age  $\geq$  2 years;
4. Failure of 2 preferred agents for LGS (e.g., clonazepam, valproic acid (divalproex), lamotrigine, topiramate, felbamate), unless all are contraindicated or clinically significant adverse effects are experienced;
5. Dose does not exceed 40 mg per day (2 tablets per day, or 16 mL per day).

**Approval duration: 12 months**

##### **B. Intractable/Refractory Epilepsy (off-label) (must meet all):**

1. Diagnosis of intractable/refractory epilepsy;
2. Prescribed by or in consultation with a neurologist;
3. Age  $\geq$  2 years;
4. Failure of  $\geq$  4 anti-seizure drugs (*see Appendix B*), unless all are contraindicated or clinically significant adverse effects are experienced;
5. Dose does not exceed 40 mg per day (2 tablets per day, or 16 mL per day).

**Approval duration: 12 months**

##### **C. Dravet Syndrome (off-label) (must meet all):**

1. Diagnosis of Dravet syndrome;
2. Prescribed by or in consultation with a neurologist;

3. Age  $\geq$  2 years;
4. Dose does not exceed 2 mg/kg per day.

**Approval duration: 12 months**

**D. Other diagnoses/indications**

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): HIM.PHAR.21 for health insurance marketplace and CP.PMN.53 for Medicaid.

**II. Continued Therapy**

**A. All Indications in Section I (must meet all):**

1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Onfi for Lennox-Gastaut syndrome, intractable/refractory epilepsy, or Dravet syndrome and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. If request is for a dose increase, new dose does not exceed one of the following (a or b):
  - a. LGS or intractable/refractory epilepsy: 40 mg per day (2 tablets per day, or 16 mL per day);
  - b. Dravet syndrome: 2 mg/kg per day.

**Approval duration: 12 months**

**B. Other diagnoses/indications (must meet 1 or 2):**

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.  
**Approval duration: Duration of request or 12 months (whichever is less);** or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): HIM.PHAR.21 for health insurance marketplace and CP.PMN.53 for Medicaid.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – HIM.PHAR.21 for health insurance marketplace and CP.PMN.53 for Medicaid or evidence of coverage documents.

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

FDA: Food and Drug Administration

LGS: Lennox-Gastaut syndrome

*Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.*

<b>Drug Name</b>	<b>Dosing Regimen</b>	<b>Dose Limit/ Maximum Dose</b>
<b>Anticonvulsants-benzodiazepines</b>		
clonazepam (Klonopin <sup>®</sup> )	See full prescribing information	See full prescribing information
diazepam rectal gel (Diastat <sup>®</sup> )		
<b>Carbamates</b>		
felbamate (Felbatol <sup>®</sup> )	See full prescribing information	See full prescribing information
<b>GABA modulators</b>		
vigabatrin (Sabril <sup>®</sup> )	See full prescribing information	See full prescribing information
tiagabine (Gabitril <sup>®</sup> )		
<b>Hydantoins</b>		
Peganone <sup>®</sup> (ethotoin)	See full prescribing information	See full prescribing information
phenytoin (Dilantin <sup>®</sup> )		
<b>Succinimides</b>		
ethosuximide (Zarontin <sup>®</sup> )	See full prescribing information	See full prescribing information
Celontin <sup>®</sup> (methsuximide)		
<b>Valproic acid</b>		
divalproex sodium (Depakote <sup>®</sup> )	See full prescribing information	See full prescribing information
valproic acid (Depakene <sup>®</sup> )		
<b>AMPA glutamate receptor antagonists</b>		
Fycompa <sup>®</sup> (perampanel)	See full prescribing information	See full prescribing information
<b>Anticonvulsants-miscellaneous</b>		
Briviact <sup>®</sup> [brivaracetam], carbamazepine [Tegretol <sup>®</sup> , Tegretol XL <sup>®</sup> ], Aptiom <sup>®</sup> [eslicarbazepine], Potiga <sup>®</sup> [ezogabine], gabapentin [Neurontin <sup>®</sup> ], Vimpat <sup>®</sup> [lacosamide], lamotrigine [Lamictal <sup>®</sup> ], levetiracetam [Keppra <sup>®</sup> , Spritam <sup>®</sup> ], oxcarbazepine [Oxtellar XR <sup>®</sup> , Trileptal <sup>®</sup> ], Lyrica <sup>®</sup> [pregabalin], primidone [Mysoline <sup>®</sup> ], Banzel <sup>®</sup> [rufinamide], topiramate [Topamax <sup>®</sup> , Qudexy XR <sup>®</sup> , Trokendi XR <sup>®</sup> ], zonisamide [Zonegran <sup>®</sup> ]	See full prescribing information	See full prescribing information

*Therapeutic alternatives are listed as Brand name<sup>®</sup> (generic) when the drug is available by brand name only and generic (Brand name<sup>®</sup>) when the drug is available by both brand and generic.*

*Appendix C: Contraindications/Boxed Warnings*

- Contraindication(s): history of hypersensitivity to the drug or its ingredients
- Boxed warning(s): risks from concomitant use with opioids

**V. Dosage and Administration**

Indication	Dosing Regimen	Maximum Dose
LGS	<p>Patients ≤ 30 kg body weight: initiate at 5 mg PO daily and titrate as tolerated up to 20 mg daily</p> <p>Patients &gt; 30 kg body weight: initiate at 10 mg PO daily and titrate as tolerated up to 40 mg daily</p> <p>A daily dose of Onfi greater than 5 mg should be administered in divided doses twice daily; a 5 mg daily dose can be administered as a single dose.</p>	<p>≤ 30 kg body weight: 20 mg/day</p> <p>&gt; 30 kg body weight: 40 mg/day</p>
Intractable/refractory epilepsy (off-label)	See LGS	See LGS
Dravet syndrome (off-label)	<p>Initial: 0.2-0.3 mg/kg/day PO</p> <p>Maximum: 0.5-2 mg/kg/day PO</p>	See regimen

**VI. Product Availability**

- Tablet with a functional score: 10 mg, 20 mg
- Oral suspension: 2.5 mg/mL in 120 mL bottles

**VII. References**

1. Onfi Prescribing Information. Deerfield, IL: Lundbeck; June 2018. Available at: <https://www.onfihcp.com/>. Accessed September 18, 2018.
2. Hancock EC, Cross JH. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev. 2013 Feb 28;(2).
3. Arzimanoglou A, French J, Blume WT, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol. 2009 Jan;8(1):82-93.
4. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2004 Apr 27;62(8):1261-73.
5. Mills JK, Lewis TG, Mughal K, et al. Retention rate of clobazam, topiramate and lamotrigine in children with intractable epilepsies at 1 year. Seizure. 2011 June;20(5): 402-405.
6. Gauthier AC, Mattson RH. Clobazam: a safe, efficacious, and newly rediscovered therapeutic for epilepsy. CNS Neurosci Ther. 2015 Jul;21(7):543-8.
7. Montenegro MA, Arif H, Nahm EA, et al. Efficacy of clobazam as add-on therapy for refractory epilepsy: experience at a US epilepsy center. Clin Neuropharmacol. 2008 Nov-Dec;31(6):333-8.

8. Cross JH, Auvin S, Falip M, et al. Expert Opinion on the Management of Lennox–Gastaut Syndrome: Treatment Algorithms and Practical Considerations. *Frontiers in Neurology*. 2017;8:505.
9. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2018. Available at: <http://www.clinicalpharmacology-ip.com/>. Accessed May 3, 2018.
10. Wirrell EC, Laux L, Jette N, et al. Optimizing the diagnosis and management of Dravet syndrome: recommendations from a North American consensus panel. *Pediatr Neurol*. 2017; 68: 18-34.
11. Epilepsies: diagnosis and management. National Institute for Health and Care Excellence (NICE) website. <https://www.nice.org.uk/guidance/CG137/chapter/Appendix-E-Pharmacological-treatment>. Updated April 2018. Accessed August 22, 2018.
12. Wirrell EC. Treatment of Dravet syndrome. *Can J Neurol Sci*. 2016; 43 Suppl 3: S13-8. doi: 10.1017/cjn.2016.249. <https://www.ncbi.nlm.nih.gov/pubmed/27264138>.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Added Onfi suspension under available brands. Updated References to reflect current literature search.	11.13	11.13
Updated references. Revised concomitant use drug list.	12.14	12.14
Removed rufinamide from trial and failure drugs. Updated references.	05.15	05.15
Converted to new policy template Updated references to reflect current literature search. Removed removal criteria: If documentation shows improvement in symptoms over prior treatments as this cannot be measured. Updated initial criteria bullet point# D to include duration for t/f of pdl for at least 4 weeks within the past 180 days. Added to renewal criteria: bullet point (a) patient previously on medication through health plan, and (b) dose does not exceed FDA limit per patient’s weight. Updated background information including description, mechanism of action.	02.16	05.16
Lennox-Gastaut: modified requirement related to treatment failure with clonazepam in conjunction with a PDL anticonvulsant to allow trial and failure of any 2 PDL anti-epileptics for Lennox-Gastaut since a neurologist is involved in the patient’s care; removed requirement that Onfi “must be used as adjunctive therapy with any of the following PDL anticonvulsants: valproic acid (divalproex), lamotrigine, topiramate, or felbamate” since specialist is involved in patient’s care and is better able to select appropriate therapy Created criteria for treatment of intractable/refractory epilepsy (off-label) Converted to new template- Removed age restriction per new template update Modified weight-based dose criteria to max dose of drug per new template update	03.17	05.17

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Added criteria for continuity of care and documentation of positive response to therapy for re-auth. Updated references		
2Q 2018 annual review: no significant HIM added; added age; added QL of 2 tablets/day, or 16 mL/day to max dose; increased initial approval duration from 6 to 12 months; references reviewed and updated.	12.18.17	05.18
3Q 2018 annual review: LGS-removed duration of trial of formulary alternatives since specialist is involved in care; references reviewed and updated.	05.03.18	08.18
Added criteria for off-label use in Dravet syndrome.	09.20.18	11.18

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise

professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:**

**For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

**For Health Insurance Marketplace members**, when applicable, this policy applies only when the prescribed agent is on your health plan approved formulary. Request for non-formulary drugs must be reviewed using the formulary exception policy.

©2012 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene<sup>®</sup> and Centene Corporation<sup>®</sup> are registered trademarks exclusively owned by Centene Corporation.